Anteris Technologies Announces Results for the Second Quarter of 2026
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.
How this was made
The 30-second read
Why it matters
The CMS national coverage determination for eligible procedures is positioned as the reimbursement framework required for U.S. site activation and broader adoption, and the company reports first U.S. patients enrolled and treated in May 2026.
Market read
This is a company-specific execution update combining a U.S. reimbursement milestone with the start of U.S. recruitment, plus quarterly cash outflow details.
What to watch
The article does not provide updated guidance, enrollment targets, or trial timeline changes beyond reimbursement-driven site activation expectations, so traders may discount the impact until enrollment metrics and safety/efficacy data progress.
Background
Anteris is advancing the DurAVR THV via the global pivotal PARADIGM Trial, comparing DurAVR to commercially available TAVRs.
Ticker impact
Anteris says it secured U.S. Medicare reimbursement eligibility for the PARADIGM Trial and initiated U.S. patient recruitment in May 2026.
Likely positive bias for the stock as traders price improved probability of trial momentum and site activation, though dilution/cash burn risk remains.
The article discloses a concrete regulatory-reimbursement milestone (CMS national coverage policy) tied to trial enrollment mechanics, plus first U.S. patients treated, which can change near-term expectations for trial progress. It also provides cash outflow context ($20.8m net operating cash outflow) that can temper the upside.
Market effects
Structural heart and TAVR device peers may see read-across interest if reimbursement frameworks reduce enrollment friction for competing trial designs.
U.S. trial execution momentum improves the company’s near-term U.S. commercialization pathway versus Europe-only progress.
CMS coverage and multi-country regulatory clearances reinforce the broader global development plan for transcatheter aortic valve therapies.
Counterpoint
Reimbursement eligibility does not guarantee enrollment pace or eventual trial outcomes; cash burn and manufacturing scaling could still dominate near-term valuation.
Key entities
- companyAnteris Technologies Global Corp.
NASDAQ-listed medical device company advancing the DurAVR THV and the PARADIGM Trial.
- clinical_programPARADIGM Trial
Randomized trial evaluating DurAVR THV versus commercially available TAVRs, with a primary endpoint at one year.
- regulatorCenters for Medicare & Medicaid Services (CMS)
U.S. agency whose national coverage policy enabled Medicare reimbursement eligibility for eligible trial procedures.
- productDurAVR THV
Anteris balloon-expandable transcatheter heart valve using ADAPT tissue technology.
